Novo Next-Generation Obesity Shot Falls Short of Lilly Rival

Novo Nordisk’s next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a tr...

🔗 Read more: https://www.bloomberg.com/news/videos/2026-02-23/novo-new-obesity-shot-falls-short-of-lilly-rival-video

#News #Business #Medicine #Biology #Astronomy #Economics